Eculizumab Therapy Leads to Rapid Resolution of Thrombocytopenia in Atypical Hemolytic Uremic Syndrome

Figure 2

Development of thrombocytopenia and renal failure in a patient of metastatic cholangiocarcinoma treated with gemcitabine and carboplatin and the lack of response to eculizumab therapy. Neither plasma exchange nor eculizumab therapy increased the platelet counts or improved the renal function of this case. The thrombocytopenia induced by chemotherapy was transient before renal failure occurred. Thus, the lack of platelet response to eculizumab therapy was not due to bone marrow suppression by chemotherapy. The dashed lines mark the lower limit of normal platelet count and the upper limit of serum creatinine, respectively.

(a)  

(b)